Upregulation of endogenous angiogenesis inhibitors: A mechanism of action of metronomic chemotherapy

Sylvia S.W. Ng, William D. Figg*

*Corresponding author for this work

Research output: Contribution to journalShort surveypeer-review

12 Scopus citations

Abstract

Antiangiogenic or metronomic chemotherapy, the frequent administration of conventional cytotoxic agents at low doses, is believed to target activated tumor endothelial cells. The mechanisms of action of such regimen remain poorly understood. In the March 2004 issue of Cancer Research, Hamano et al. demonstrated that low-dose cyclophosphamide inhibits tumor growth by upregulating the endogenous angiogenesis inhibitor thrombospondin-1 in tumor and perivascular cells. Thrombospondin-1, in turn, promotes endothelial cell apoptosis. It was also proposed that thrombospondin-1 levels might be used as a surrogate marker to monitor response to low-dose cyclophosphamide therapy in the clinic.

Original languageEnglish
Pages (from-to)1212-1213
Number of pages2
JournalCancer Biology and Therapy
Volume3
Issue number12
DOIs
StatePublished - Dec 2004
Externally publishedYes

Keywords

  • Angiogenesis
  • Cancer
  • Cyclophosphamide
  • Endothelial cells
  • Metronomic chemotherapy
  • Thrombospondin-1

Fingerprint

Dive into the research topics of 'Upregulation of endogenous angiogenesis inhibitors: A mechanism of action of metronomic chemotherapy'. Together they form a unique fingerprint.

Cite this